About AtriCure (NASDAQ:ATRC)
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100
Debt
Debt-to-Equity Ratio0.23%
Current Ratio2.58%
Quick Ratio1.87%
Price-To-Earnings
Trailing P/E Ratio-24.63
Forward P/E Ratio-24.63
P/E GrowthN/A
Sales & Book Value
Annual Sales$174.72 million
Price / Sales4.10
Cash FlowN/A
Price / CashN/A
Book Value$4.67 per share
Price / Book4.38
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-15.39%
Return on Equity-16.74%
Return on Assets-10.04%
Miscellaneous
Employees570
Outstanding Shares35,080,000
AtriCure (NASDAQ:ATRC) Frequently Asked Questions
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure (NASDAQ:ATRC) posted its earnings results on Monday, February, 26th. The medical device company reported ($0.08) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.13. The medical device company earned $46.06 million during the quarter, compared to the consensus estimate of $45.85 million. AtriCure had a negative return on equity of 16.74% and a negative net margin of 15.39%. AtriCure's revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.27) EPS. View AtriCure's Earnings History.
When is AtriCure's next earnings date?
What price target have analysts set for ATRC?
5 Wall Street analysts have issued 1-year price objectives for AtriCure's stock. Their forecasts range from $23.00 to $26.00. On average, they expect AtriCure's share price to reach $24.80 in the next year. View Analyst Ratings for AtriCure.
What are Wall Street analysts saying about AtriCure stock?
Here are some recent quotes from research analysts about AtriCure stock:
- 1. Needham & Company LLC analysts commented, "ATRC’s 4Q17 revenue was consistent with its 1/8/18 preannouncement while its EBITDA missed consensus and EPS beat consensus even excluding a $0.12 non-cash benefit. Management reiterated its 2018 revenue guidance of $190-196M vs. consensus of $195M. We believe the recent society guidelines, new products (AtriClip Pro-V and Flex-V), and surgeon training activities should drive strong growth. We believe that management’s more conservative guidance leaves room for upside and with ATRC shares trading at a large discount to peers (2018E EV/sales of 3.3x vs. small/mid-cap growth peers at a median of 6.4x), we reiterate our Buy rating." (2/27/2018)
- 2. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (10/2/2017)
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG) and LeMaitre Vascular (LMAT).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Mr. Michael H. Carrel, Chief Exec. Officer, Pres and Director (Age 47)
- Mr. M. Andrew Wade, Chief Financial Officer and Sr. VP (Age 43)
- Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
- Mr. Justin J. Noznesky, Sr. VP of Marketing and Bus. Devel. (Age 40)
- Mr. Karl Dahlquist, Chief Compliance Officer and VP of Legal & Compliance
Has AtriCure been receiving favorable news coverage?
News headlines about ATRC stock have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AtriCure earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news articles about the medical device company an impact score of 48.13 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of AtriCure?
Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
One share of ATRC stock can currently be purchased for approximately $20.44.
How big of a company is AtriCure?
AtriCure has a market capitalization of $743.98 million and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.
How can I contact AtriCure?
AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.
MarketBeat Community Rating for AtriCure (ATRC)
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
AtriCure (NASDAQ:ATRC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for AtriCure in the last 12 months. Their average twelve-month price target is $24.80, suggesting that the stock has a possible upside of 21.33%. The high price target for ATRC is $26.00 and the low price target for ATRC is $23.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.86 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.80 | $24.80 | $24.3333 | $25.8333 |
| Price Target Upside: | 21.33% upside | 35.37% upside | 37.24% upside | 10.21% upside |
AtriCure (NASDAQ:ATRC) Consensus Price Target History
AtriCure (NASDAQ:ATRC) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
AtriCure (NASDAQ:ATRC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AtriCure (NASDAQ ATRC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.70%
Institutional Ownership Percentage: 86.23%
AtriCure (NASDAQ ATRC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/13/2018 | Elizabeth D Krell | Director | Sell | 10,000 | $20.00 | $200,000.00 | |  |
| 3/1/2018 | Regina E Groves | Director | Buy | 1,000 | $17.43 | $17,430.00 | | |
| 2/15/2018 | Justin J Noznesky | SVP | Sell | 4,000 | $17.03 | $68,120.00 | | |
| 11/30/2017 | M. Andrew Wade | CFO | Sell | 2,000 | $18.41 | $36,820.00 | | |
| 11/8/2017 | B Kristine Johnson | Director | Buy | 1,500 | $18.36 | $27,540.00 | 10,969 | |
| 8/22/2017 | Elizabeth D Krell | Director | Sell | 10,000 | $22.40 | $224,000.00 | 29,967 | |
| 5/17/2017 | Elizabeth D Krell | Director | Sell | 10,000 | $21.44 | $214,400.00 | 24,162 | |
| 3/17/2017 | Andrew L Lux | SVP | Sell | 20,000 | $18.85 | $377,000.00 | 85,589 | |
| 11/15/2016 | Elizabeth D Krell | Director | Sell | 10,000 | $19.73 | $197,300.00 | 24,162 | |
| 9/13/2016 | Elizabeth D Krell | Director | Sell | 6,000 | $15.93 | $95,580.00 | 20,162 | |
| 8/17/2016 | Elizabeth D Krell | Director | Sell | 5,000 | $15.20 | $76,000.00 | 15,162 | |
| 3/8/2016 | Elizabeth D Krell | Director | Sell | 10,000 | $16.91 | $169,100.00 | 17,162 | |
| 12/3/2015 | Douglas J. Seith | COO | Sell | 5,000 | $21.55 | $107,750.00 | 125,215 | |
| 12/2/2015 | Elizabeth D. Krell | Director | Sell | 10,000 | $21.88 | $218,800.00 | 7,162 | |
| 11/11/2015 | Elizabeth D. Krell | Director | Sell | 10,000 | $20.68 | $206,800.00 | 7,162 | |
| 4/1/2015 | Michael D Hooven | Director | Sell | 142,268 | $20.81 | $2,960,597.08 | | |
| 3/31/2015 | Michael D Hooven | Director | Sell | 20,000 | $20.51 | $410,200.00 | | |
| 3/30/2015 | Michael D Hooven | Director | Sell | 85,000 | $21.01 | $1,785,850.00 | | |
| 3/13/2015 | Karen P Robards | Director | Sell | 3,150 | $19.53 | $61,519.50 | | |
| 3/5/2015 | Douglas J Seith | COO | Sell | 36,688 | $17.51 | $642,406.88 | | |
| 3/2/2015 | Elizabeth D Krell | Director | Sell | 10,000 | $17.63 | $176,300.00 | | |
| 5/6/2014 | Douglas Seith | SVP | Buy | 1,000 | $15.04 | $15,040.00 | 95,694 | |
| 9/13/2013 | Richard Johnston | Insider | Sell | 77,610 | $10.00 | $776,100.00 | | |
| 8/12/2013 | Douglas Seith | SVP | Buy | 10,000 | $9.58 | $95,800.00 | 58,240 | |
| 8/5/2013 | Richard Johnston | Insider | Sell | 20,047 | $10.00 | $200,470.00 | | |
| 7/11/2013 | Richard M Johnston | Insider | Sell | 2,343 | $10.00 | $23,430.00 | | |
| 6/19/2013 | Richard M Johnston | Insider | Sell | 29,348 | $8.96 | $262,958.08 | | |
| 6/18/2013 | Richard M Johnston | Insider | Sell | 39,682 | $9.18 | $364,280.76 | | |
| 6/14/2013 | Richard M Johnston | Insider | Sell | 95,598 | $8.97 | $857,514.06 | | |
| 6/12/2013 | Richard M Johnston | Insider | Sell | 35,372 | $9.01 | $318,701.72 | | |
| 3/6/2013 | James L Lucky | VP | Sell | 50,065 | $8.14 | $407,529.10 | | |
| 9/14/2012 | Mark R Lanning | Director | Buy | 11,006 | $7.64 | $84,085.84 | | |
| 9/13/2012 | Michael D Hooven | Director | Buy | 1,110 | $7.37 | $8,180.70 | | |
| 9/12/2012 | Michael D Hooven | Director | Buy | 1,150 | $7.10 | $8,165.00 | | |
| 9/11/2012 | Michael D Hooven | Director | Buy | 1,145 | $7.18 | $8,221.10 | | |
| 9/10/2012 | Michael D Hooven | Director | Buy | 1,215 | $7.15 | $8,687.25 | | |
| 9/7/2012 | Michael D Hooven | Director | Buy | 1,215 | $6.88 | $8,359.20 | | |
| 8/23/2012 | Karen P Robards | Director | Buy | 1,000 | $6.70 | $6,700.00 | | |
| 8/16/2012 | Karen P Robards | Director | Buy | 1,000 | $6.98 | $6,980.00 | | |
(Data available from 1/1/2013 forward)
AtriCure (NASDAQ ATRC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Reviewing AtriCure (ATRC) & Nuvectra (NVTR)
www.americanbankingnews.com - April 24 at 3:16 PM |
| AtriCure (ATRC) Expected to Announce Quarterly Sales of $45.77 Million
www.americanbankingnews.com - April 21 at 4:20 AM |
| AtriCure (ATRC) Expected to Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - April 19 at 9:51 AM |
| BidaskClub Downgrades AtriCure (ATRC) to Buy
www.americanbankingnews.com - April 16 at 7:00 PM |
 | Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)?
finance.yahoo.com - April 10 at 5:47 PM |
| Free Post Earnings Research Report: AtriCure’s Quarterly Revenues Jumped 11.9%; Net Loss Narrowed
finance.yahoo.com - April 9 at 8:22 AM |
| AtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.77 Million
www.americanbankingnews.com - April 4 at 3:58 AM |
| -$0.26 EPS Expected for AtriCure Inc. (ATRC) This Quarter
www.americanbankingnews.com - April 2 at 9:12 AM |
| AtriCure (ATRC) Given New $25.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - April 2 at 8:39 AM |
| AtriCure (ATRC) Given New $24.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - April 1 at 10:52 PM |
| AtriCure Inc. (ATRC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 1 at 9:36 AM |
| AtriCure's (ATRC) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - March 28 at 2:06 PM |
| AtriCure (ATRC) Given New $26.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 24 at 9:30 PM |
| AtriCure (ATRC) Upgraded at TheStreet
www.americanbankingnews.com - March 24 at 12:28 AM |
| AtriCure (ATRC) versus Rockwell Medical (RMTI) Critical Comparison
www.americanbankingnews.com - March 20 at 3:19 AM |
| AtriCure (ATRC) Upgraded at BidaskClub
www.americanbankingnews.com - March 17 at 3:54 PM |
| Zacks: Analysts Expect AtriCure Inc. (ATRC) Will Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - March 16 at 7:33 AM |
| AtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
finance.yahoo.com - March 15 at 9:12 AM |
| Elizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - March 14 at 7:49 PM |
| SeaSpine (SPNE) & AtriCure (ATRC) Head to Head Review
www.americanbankingnews.com - March 12 at 3:10 AM |
| Meridian Bioscience (VIVO) versus AtriCure (ATRC) Head-To-Head Review
www.americanbankingnews.com - March 10 at 4:18 PM |
 | Active-Investors: Free Research Report as ConforMIS Reported Better Than Expected Results
www.finanznachrichten.de - March 9 at 9:21 AM |
| Free Research Report as ConforMIS Reported Better Than Expected Results
finance.yahoo.com - March 9 at 9:21 AM |
| AtriCure Inc. (ATRC) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 7 at 2:02 PM |
| AtriCure Inc. (ATRC) Position Raised by Tamarack Advisers LP
www.americanbankingnews.com - March 6 at 10:30 AM |
| Royce & Associates LP Increases Holdings in AtriCure Inc. (ATRC)
www.americanbankingnews.com - March 2 at 10:44 AM |
| Report: Developing Opportunities within LCI Industries, Biglari, Graco, Federal Signal, AtriCure, and Perry Ellis International — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 2 at 8:09 AM |
| Regina E. Groves Acquires 1,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - March 1 at 10:44 PM |
| $46.55 Million in Sales Expected for AtriCure Inc. (ATRC) This Quarter
www.americanbankingnews.com - March 1 at 8:58 AM |
| AtriCure Inc. (ATRC) Expected to Earn Q1 2018 Earnings of ($0.29) Per Share
www.americanbankingnews.com - March 1 at 8:36 AM |
| AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 1 at 8:22 AM |
| AtriCure Inc. to Post FY2022 Earnings of $0.22 Per Share, Leerink Swann Forecasts (ATRC)
www.americanbankingnews.com - February 28 at 4:51 PM |
| AtriCure Inc. (ATRC) Shares Sold by Cortina Asset Management LLC
www.americanbankingnews.com - February 28 at 1:27 PM |
 | AtriCure's (ATRC) CEO Mike Carrel on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 5:52 PM |
| AtriCure (ATRC) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 27 at 9:46 AM |
| AtriCure (ATRC) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - February 27 at 8:22 AM |
| AtriCure, Inc. to Host Earnings Call
finance.yahoo.com - February 26 at 5:43 PM |
| AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 26 at 5:43 PM |
 | AtriCure Q4 Earnings Outlook
feeds.benzinga.com - February 26 at 12:16 PM |
| AlphaOne Investment Services LLC Has $4.19 Million Stake in AtriCure Inc. (ATRC)
www.americanbankingnews.com - February 26 at 5:14 AM |
| BidaskClub Upgrades AtriCure (ATRC) to Hold
www.americanbankingnews.com - February 25 at 12:00 AM |
| Neurometrix (NURO) vs. AtriCure (ATRC) Critical Review
www.americanbankingnews.com - February 24 at 9:18 AM |
| AtriCure Launches the AtriClip® FLEX•V™ Device in the United States
finance.yahoo.com - February 22 at 8:02 AM |
| Cincinnati medical device maker gets board refresh
finance.yahoo.com - February 20 at 5:43 PM |
| AtriCure Names Scott Drake Board Chairman
finance.yahoo.com - February 20 at 8:03 AM |
| AtriCure (ATRC) to Release Earnings on Monday
www.americanbankingnews.com - February 19 at 3:46 AM |
| AtriCure (ATRC) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - February 17 at 11:36 PM |
| AtriCure Inc. (ATRC) SVP Justin J. Noznesky Sells 4,000 Shares
www.americanbankingnews.com - February 16 at 10:20 PM |
| AtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.45 Million
www.americanbankingnews.com - February 12 at 3:56 AM |
| -$0.21 Earnings Per Share Expected for AtriCure Inc. (ATRC) This Quarter
www.americanbankingnews.com - February 10 at 3:12 PM |
AtriCure (NASDAQ:ATRC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AtriCure (NASDAQ:ATRC) Income Statement, Balance Sheet and Cash Flow Statement
AtriCure (NASDAQ ATRC) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
